SURGERY PARTNERS ($SGRY) posted quarterly earnings results for Q1 2026 on Tuesday, May 5th. The company reported earnings of -$0.03 per share, beating estimates of -$0.12 by $0.09. The company also reported revenue of $810,900,000, missing estimates of $813,850,115 by $-2,950,115.
You can see Quiver Quantitative's $SGRY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SURGERY PARTNERS Insider Trading Activity
SURGERY PARTNERS insiders have traded $SGRY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $SGRY stock by insiders over the last 6 months:
- JASON ERIC EVANS (Chief Executive Officer) has made 0 purchases and 2 sales selling 31,862 shares for an estimated $412,448.
- DAVID T DOHERTY (Chief Financial Officer) has made 0 purchases and 2 sales selling 23,441 shares for an estimated $312,541.
- JENNIFER BALDOCK (Chief Admin & Dev Officer) has made 0 purchases and 2 sales selling 15,880 shares for an estimated $214,483.
- MARISSA BRITTENHAM (Chief Strategy Officer) has made 0 purchases and 2 sales selling 12,442 shares for an estimated $166,213.
- DANIELLE BURKHALTER (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 11,205 shares for an estimated $149,716.
- WILLIAM TRENTON WEBB (American Group President) has made 0 purchases and 2 sales selling 2,066 shares for an estimated $28,653.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
SURGERY PARTNERS Hedge Fund Activity
We have seen 85 institutional investors add shares of SURGERY PARTNERS stock to their portfolio, and 116 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 4,113,052 shares (+111.4%) to their portfolio in Q4 2025, for an estimated $63,546,653
- FMR LLC removed 3,911,694 shares (-37.3%) from their portfolio in Q4 2025, for an estimated $60,435,672
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,079,634 shares (-73.7%) from their portfolio in Q4 2025, for an estimated $47,580,345
- DAVIDSON KEMPNER CAPITAL MANAGEMENT LP added 2,371,464 shares (+inf%) to their portfolio in Q4 2025, for an estimated $36,639,118
- PENTWATER CAPITAL MANAGEMENT LP removed 1,681,000 shares (-14.4%) from their portfolio in Q4 2025, for an estimated $25,971,450
- INVESCO LTD. removed 1,576,138 shares (-89.6%) from their portfolio in Q4 2025, for an estimated $24,351,332
- NOMURA HOLDINGS INC added 1,495,555 shares (+665.9%) to their portfolio in Q4 2025, for an estimated $23,106,324
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
SURGERY PARTNERS Analyst Ratings
Wall Street analysts have issued reports on $SGRY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 11/17/2025
- UBS issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for SURGERY PARTNERS, check out Quiver Quantitative's $SGRY forecast page.
SURGERY PARTNERS Price Targets
Multiple analysts have issued price targets for $SGRY recently. We have seen 7 analysts offer price targets for $SGRY in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Ann Hynes from Mizuho set a target price of $17.0 on 03/05/2026
- A.J. Rice from UBS set a target price of $21.0 on 03/05/2026
- Ryan Langston from TD Cowen set a target price of $20.0 on 03/05/2026
- Ben Hendrix from RBC Capital set a target price of $20.0 on 03/04/2026
- Andrew Mok from Barclays set a target price of $14.0 on 03/03/2026
- Benjamin Rossi from JP Morgan set a target price of $20.0 on 11/24/2025
- Bill Sutherland from Benchmark set a target price of $30.0 on 11/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
